Filtered By:
Education: Study
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 2114 results found since Jan 2013.

Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment.
Authors: Javalkar V, Kuybu O, Amireh A, Kelley RE Abstract The optimization of antithrombotic therapy for acute stroke treatment and secondary prevention is an evolving process based on an increasing array of studies that provide an evidence-based approach. Options have increased dramatically with the release of the non-vitamin K oral anticoagulants and with the results of recent randomized clinical trials designed to assess potential benefits versus risks for patients in an individualized fashion. Recent studies have provided important information to guide choice and dosing of antiplatelet agents as well as the le...
Source: Southern Medical Journal - November 5, 2020 Category: General Medicine Tags: South Med J Source Type: research

DNA methylation analyses identify an intronic < i > ZDHHC6 < /i > locus associated with time to recurrent stroke in the Vitamin Intervention for Stroke Prevention (VISP) clinical trial
by Nicole M. Davis Armstrong, Wei-Min Chen, Fang-Chi Hsu, Michael S. Brewer, Natalia Cullell, Israel Fern ández-Cadenas, Stephen R. Williams, Michèle M. Sale, Bradford B. Worrall, Keith L. Keene Aberrant DNA methylation profiles have been implicated in numerous cardiovascular diseases; however, few studies have investigated how these epigenetic modifications contribute to stroke recurrence. The aim of this study was to identify methylation loci associated with the time to recurrent cerebr o- and cardiovascular events in individuals of European and African descent. DNA methylation profiles were generated for 180 individu...
Source: PLoS One - July 12, 2021 Category: Biomedical Science Authors: Nicole M. Davis Armstrong Source Type: research

Predicting the Risk of Ischemic Stroke in Patients Treated with Novel Oral Anticoagulants: A Machine Learning Approach
Conclusions: The stroke risk in AF patients treated with NOAC could be predicted based on comorbidities like ischemic heart diseases, urinary tract infections, and dementia additionally to age and male sex. Knowing and addressing these factors may help reduce the risk of stroke in this patient population.Neuroepidemiology
Source: Neuroepidemiology - July 21, 2021 Category: Epidemiology Source Type: research

Effect of Vitamin D Supplementation on the Prognosis of Post-stroke Fatigue: A Retrospective Cohort Study
Conclusions: Our results indicated that vitamin D supplementation could improve fatigue symptoms and neurological outcomes in PSF patients with vitamin D deficiency. Subject to replication in other settings, a randomized controlled trial (RCT) might be undertaken to validate the potential beneficial impact of vitamin D supplementation in post-stroke patients found to be vitamin D deficient.
Source: Frontiers in Neurology - November 5, 2021 Category: Neurology Source Type: research

Antiplatelet Agents and Oral Anticoagulant Use in Patients with Atrial Fibrillation and Carotid Artery Disease After First-Time Ischaemic Stroke
CONCLUSIONS: The results suggest for patients with AF and carotid artery disease after ischaemic stroke, receiving NOACs without APA is associated with a lower risk of major bleeding with no negative impact on recurrent stroke or mortality. Evidence from randomised trials is needed to confirm this finding.PMID:36692658 | DOI:10.1007/s10557-023-07433-4
Source: Atherosclerosis - January 24, 2023 Category: Cardiology Authors: Stephanie L Harrison Benjamin J R Buckley Deirdre A Lane Elnara Fazio-Eynullayeva Paula Underhill Andrew Hill David J Werring Gregory Y H Lip Source Type: research

Oral Anticoagulation and the Incidence of Stroke Associated with Atrial Fibrillation in Mainland Portugal: A Modelling Study
CONCLUSION: The use of oral anticoagulation was associated with a reduced incidence of stroke in patients with atrial fibrillation in mainland Portugal. This reduction was more relevant in the period between 2016 and 2018, and is probably related with the introduction of the novel oral anticoagulants.PMID:37429703 | DOI:10.20344/amp.19255
Source: Acta Medica Portuguesa - July 10, 2023 Category: General Medicine Authors: Raquel Ascen ção Madalena Gil Francisco Louren ço Daniel Caldeira Ros ário Oliveira Margarida Borges Lu ís Silva Miguel Jo ão Costa Source Type: research

Reservations against new oral anticoagulants after stroke and cerebral bleeding
Abstract: Dabigatran, rivaroxaban, and apixaban are the new oral anticoagulants (NOAC) which have been investigated in patients with atrial fibrillation (AF) for primary and secondary prevention of stroke and thromboembolism. In these trials NOAC had a similar efficacy and safety profile compared to traditional vitamin-K-antagonists such as warfarin. We advise caution in the use of NOAC in patients with stroke or cerebral hemorrhage because of the following reasons:1) Patients with cerebral bleeding were excluded from the trials. 2) Stroke within 14days and severe stroke within 6months before screening were exclusion crite...
Source: Journal of the Neurological Sciences - April 29, 2013 Category: Neurology Authors: Claudia Stöllberger, Josef Finsterer Tags: Opinion Source Type: research

Novel oral anticoagulants in secondary prevention of stroke
In patients with atrial fibrillation (AF) oral anticoagulation with vitamin-K antagonists (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention yielding a 60–70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26 percent. Vitamin-K antagonists have a number of well documented shortcomings. Recently the results of randomised trials for three new oral anticoagulants that do not exhibit the limitations of vitamin-K antagonists have been published. These include direct factor Xa inhibitors (rivaroxaban and apixaban) and a direct thrombin inhibitor...
Source: Best Practice and Research. Clinical Haematology - June 1, 2013 Category: Hematology Authors: H.C. Diener, J.D. Easton, G.J. Hankey, R.G. Hart Source Type: research

Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
Background: Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may have a higher risk of thrombosis and/or bleeding than VKA-experienced patients.Methods and results: Using data from ARISTOTLE, we assessed baseline characteristics and the treatment effect of apixaban versus warfarin in the VKA-naive and VKA-experienced cohorts. We compared rates of study drug discontinuation and time-in-therapeutic range. Overall, 7,800 (43%) were VKA naive, and 10,401 were VKA experienced. At baseline, both groups were similar with respect to age and congestive heart failure, hypertension, age, diabetes, stroke sco...
Source: American Heart Journal - July 26, 2013 Category: Cardiology Authors: David A. Garcia, Lars Wallentin, Renato D. Lopes, Laine Thomas, John H. Alexander, Elaine M. Hylek, Jack Ansell, Michael Hanna, Fernando Lanas, Greg Flaker, Patrick Commerford, Denis Xavier, Dragos Vinereanu, Hongqiu Yang, Christopher B. Granger Tags: Electrophysiology Source Type: research

Novel oral anticoagulants in secondary prevention of stroke
In patients with atrial fibrillation (AF) oral anticoagulation with vitamin-K antagonists (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention yielding a 60–70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26 percent. Vitamin-K antagonists have a number of well documented shortcomings. Recently the results of randomised trials for three new oral anticoagulants that do not exhibit the limitations of vitamin-K antagonists have been published. These include direct factor Xa inhibitors (rivaroxaban and apixaban) and a direct thrombin inhibitor...
Source: Best Practice and Research. Clinical Haematology - June 1, 2013 Category: Hematology Authors: H.C. Diener, J.D. Easton, G.J. Hankey, R.G. Hart Source Type: research

Reasons Underlying Non-Adherence to and Discontinuation of Anticoagulation in Secondary Stroke Prevention among Patients with Atrial Fibrillation
Conclusion: Nonadherence to OAC in stroke patients results from fear of potential complications or inconvenience and physicians' concerns regarding functional status. OAC should be initiated wherever possible during the in-hospital stay.Eur Neurol 2015;73:184-191
Source: European Neurology - January 24, 2015 Category: Neurology Source Type: research

The Use of Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients with History of Intra-Cranial Hemorrhage.
CONCLUSIONS: -Warfarin use may be beneficial for AF patients with prior ICH having a CHA2DS2-VASc score ≥6. Whether the use of non-vitamin K antagonist oral anticoagulants (NOACs) could lower the threshold for treatment deserves further study. PMID: 26969761 [PubMed - as supplied by publisher]
Source: Circulation - March 11, 2016 Category: Cardiology Authors: Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA Tags: Circulation Source Type: research